SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending following a proposed flat rate for Medicare Advantage payments in 2027 by the Trump administration, dramatically below industry expectations. This news, surfacing just before its earnings report, triggered a significant sell-off across the healthcare sector, with the community divided between panicked investors and those eyeing the dip as a prime buying opportunity. Many anticipate future negotiations or a rebound, viewing the sharp drop as an overreaction or market manipulation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is captivating the market after silver reached historic price levels, sparking a heated debate among traders about its sustainability. While some bulls anticipate continued parabolic gains driven by industrial demand and geopolitical factors, a significant bearish contingent warns of an imminent pullback, pointing to extreme volatility and potential market manipulation.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a trending topic, propelled by an exclusive AI licensing partnership for its Engagement Language Model in Africa, fueling immense community excitement. Traders are actively discussing the potential for a significant short squeeze, pushing for triple-digit price targets amidst warnings from bears about its rapid ascent.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending due to proposed flat Medicare Advantage payment rates for 2027 by CMS, which are significantly below analyst expectations and signal potential margin pressure for MA-heavy insurers. This news has sparked a sector-wide re-evaluation and a notable sell-off, despite recent reaffirmations of guidance and improved star ratings for some of its plans. The community is actively debating whether this is an overblown reaction, similar to past regulatory shocks, or if it indicates a more sustained challenge to profitability.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is actively trending as the community eagerly anticipates a significant NASA Lunar Terrain Vehicle (LTV) contract award, positioning the company as a leading contender in the burgeoning lunar economy. Investors are closely watching for this pivotal announcement, alongside the company's crucial role in communications and data tracking for the upcoming Artemis II mission, fueling speculation about its future trajectory within the space sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending following a significant $1.6 billion U.S. government investment through the CHIPS Program, coupled with a $1.5 billion private placement, aimed at securing a domestic rare earth supply chain. The community is actively discussing this strategic backing as a catalyst for substantial long-term growth and reduced reliance on foreign sources, drawing comparisons to past government-supported entities. Despite an initial price surge followed by a notable pullback, discussions persist about the long-term potential, short covering, and strategic importance of rare earth minerals for national security, though some voice concerns about valuation and 'pump' dynamics.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is attracting significant attention due to its expanding pipeline with acquired anticoagulant assets and ongoing advancements for its lead candidate, Tecarfarin, which holds FDA Fast Track and Orphan Drug designations. The community is sharply divided, with strong enthusiasm for its potential to modernize anticoagulation contrasting with skepticism around cash runway, dilution concerns, and allegations of promotional bot activity.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

The immediate catalyst driving conversations around CVS Health is the proposed essentially flat Medicare Advantage payment rates for 2027 by CMS, significantly below market expectations. This development is broadly perceived as a policy-driven margin squeeze risk for the healthcare sector, with the community actively discussing potential prolonged multiple compression and de-risking across MA-heavy insurers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending after Nvidia announced a $2 billion investment to accelerate the buildout of its AI data centers, which many interpret as a strong validation of its critical role in the AI infrastructure revolution. While some view this deepened partnership as a significant bullish catalyst, others remain skeptical, citing the discounted share purchase as a potential bailout for the unprofitable and highly indebted company. The community is actively debating whether this capital infusion strengthens CoreWeave's long-term stability or is a stopgap measure.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

Cel-Sci is drawing significant attention after its CEO made a substantial share purchase, which the community interprets as a strong signal of confidence. Investors are actively debating the potential approval of Multikine for Breakthrough Medicine Designation by the Saudi SFDA, a decision closely watched for its market entry implications amidst ongoing discussions about the drug's clinical trial history and broader financial strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 23rd. The shares were sold at an average price of...

Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX

Mitsubishi UFJ Trust & Banking Corp reduced its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 11.6% in the third quarter, according to its most recent filing with the SEC...

Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX

Cullen Frost Bankers Inc. boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 44.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last?

Dianthus Therapeutics, Inc. (DNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lightning Round: Coherent is a winner, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Steel Dynamic, Royalty Pharma, Coherent, Lucid, and more...

Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction dated Friday, January 16th. The shares were sold at an average price...

Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the company's stock in a transaction on Friday, January 16th. The stock was sold at an average price of...

Sumitomo Mitsui Trust Group Inc. Buys 207,338 Shares of Royalty Pharma PLC $RPRX

Sumitomo Mitsui Trust Group Inc. raised its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 23.2% during the 3rd quarter, according to its most recent disclosure with the Securities and...

Royalty Pharma (NASDAQ:RPRX) Raised to "Strong-Buy" at Wall Street Zen

Wall Street Zen raised Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday...

Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX

Nordea Investment Management AB grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 18.3% during the third quarter, according to its most recent 13F filing with the Securities and...

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

Current Price	$40.47
Prev Close	$40.40
Open	$40.41
Dividend Yield	3.29%
50-Day Moving Average	$39.35
Beta	0.36
Avg. Volume	4.13M
PE Ratio	23.10

52-Week High	$41.70
52-Week Low	$29.66
Market Capitalization	$23.32B
EPS (Annual)	$1.91
Price to Book	2.70
Revenue Per Employee	$22.86M
Enterprise Value/EBITDA	N/A

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A